NCT07098364 - ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 4, 2030

Study Completion Date

October 4, 2043

Conditions

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High-Grade B-Cell LymphomaRecurrent Indolent B-Cell Non-Hodgkin LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Grade 3b Follicular LymphomaRefractory High-Grade B-Cell LymphomaRefractory Indolent B-Cell Non-Hodgkin LymphomaRefractory Primary Mediastinal Large B-Cell Lymphoma

Interventions

BIOLOGICAL

Vevoctadekin

Given SC

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Leukapheresis

Undergo leukapheresis

BIOLOGICAL

Lisocabtagene Maraleucel

Given IV

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Lymphodepletion Therapy

Undergo lymphodepletion chemotherapy

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET scan

PROCEDURE

X-Ray Imaging

Undergo x-ray

PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle